Page last updated: 2024-09-05

lapatinib and neurotensin

lapatinib has been researched along with neurotensin in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (neurotensin)	Trials (neurotensin)	Recent Studies (post-2010) (neurotensin)
1,919	305	1,442	4,054	45	544

Protein Interaction Comparison

Protein	Taxonomy	neurotensin (IC50)
Neurotensin receptor type 1	Homo sapiens (human)	0.0013
Neurotensin receptor type 2	Rattus norvegicus (Norway rat)	0.0582
Sortilin	Homo sapiens (human)	0.36

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z	1
Jensen, RT; Lee, L; Moody, TW; Ramos-Alvarez, I	1

Other Studies

2 other study(ies) available for lapatinib and neurotensin

Article	Year
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget, 2014, Sep-30, Volume: 5, Issue:18 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays	2014
Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner. European journal of pharmacology, 2019, Dec-15, Volume: 865 Topics: Cell Line, Tumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lapatinib; Neurotensin; Phosphorylation; Reactive Oxygen Species; Receptor, ErbB-2; Receptors, Neurotensin; Transcriptional Activation; Tyrosine	2019

Article

Year

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2014

Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.

European journal of pharmacology, 2019, Dec-15, Volume: 865

Topics: Cell Line, Tumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lapatinib; Neurotensin; Phosphorylation; Reactive Oxygen Species; Receptor, ErbB-2; Receptors, Neurotensin; Transcriptional Activation; Tyrosine

2019